Alpha Glucosidase Inhibitors Market to record USD 567.96 Mn incremental growth -- Driven by increase in awareness of diabetes and growing initiatives

News provided by

Sep 26, 2022, 02:15 ET

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- The "Alpha Glucosidase Inhibitors Market by Disease Type and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.

Technavio has announced its latest market research report titled Global Alpha Glucosidase Inhibitors Market 2022-2026

The potential growth difference for the alpha glucosidase inhibitors market between 2021 and 2026 is USD 567.96 million. The report identifies various factors including the prevalence rate of the disease, revenue generated by pharmaceutical companies, GDP growth, disposable income, and commodity price fluctuation among others to estimate the size of the market. Download PDF Sample Report

Key Market Dynamics:

Market Driver
Market Challenges

The increase in awareness of diabetes and growth initiatives are expected to drive the growth of the market. Government agencies and various organizations across the world are undertaking several community-level and global-level programs to tackle diabetes. For instance, in April 2021, the IDF and Direct Relief announced an initiative to supply diabetes products to vulnerable populations around the world. Similarly, The National Diabetes Services Scheme (NDSS) by the Australian Government along with Diabetes Australia focuses on enhancing the capacity of people with diabetes to understand and self-manage their condition. Diabetes Australia also seeks to support people with diabetes by providing timely, reliable, and affordable access to NDSS services. The presence of such awareness programs will drive the growth of the market during the forecast period.

In addition, the growing awareness of the benefits of alpha glucosidase inhibitors will further drive the growth of the market. However, price pressure and availability of counterfeiter drugs will challenge market growth.

The alpha glucosidase inhibitors market report is segmented by Geography (North America, Europe, Asia, and the Rest of the World (ROW)) and Disease Type (Type 2 diabetes and Dumping syndrome).

North America will dominate the market growth, occupying 42% of the global market share. The increasing prevalence of type 2 diabetes and dumping syndrome is driving the growth of the regional market.

By disease type, the market growth in the type 2 diabetes segment will be significant over the forecast period. The segment is driven by the high prevalence of type 2 diabetes.

View Our Sample Report for highlights on the contribution of various segments and regionals toward the market growth.

Key Companies Mentioned with their Offerings

Anderson Hay and Grain Co. Inc.: The company offers alpha glucosidase inhibitors such as alfalfa hay.
Bayer AG: The company offers alpha glucosidase inhibitors such as GLUCOBAY.
BioVision Inc.: The company offers various life sciences research tools required for drug discovery in disease-related areas like cancer, diabetes, obesity, Alzheimer's disease, etc.
Border Valley Trading: The company offers alpha glucosidase inhibitors for beef cattle, horses, sheep, goats, and camels.
Bristol Myers Squibb Co.: The company operates in a single segment and is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for various diseases.
AstraZeneca Plc
C. H. Boehringer Sohn AG and Co. KG
Eli Lilly and Co.
GSK Plc
Glenmark Pharmaceuticals Ltd
Merck KGaA
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi
Straight Healthcare
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.

Related Reports:

Alpha Glucosidase Inhibitors Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 2.51%
Market growth 2022-2026	USD 567.96 million
Market structure	Fragmented
YoY growth (%)	2.0
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 42%
Key consumer countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, competitive strategies, consumer engagement scope
Companies profiled	Anderson Hay and Grain Co. Inc., AstraZeneca Plc, Bayer AG, BioVision Inc., Border Valley Trading, Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Eli Lilly and Co., GSK Plc, Glenmark Pharmaceuticals Ltd, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi, Straight Healthcare, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.
Market Dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

1.1 Market overview

Exhibit 01: Executive Summary – Chart on Market Overview
Exhibit 02: Executive Summary – Data Table on Market Overview
Exhibit 03: Executive Summary – Chart on Global Market Characteristics
Exhibit 04: Executive Summary – Chart on Market by Geography
Exhibit 05: Executive Summary – Chart on Market Segmentation by Disease Type
Exhibit 06: Executive Summary – Chart on Incremental Growth
Exhibit 07: Executive Summary – Data Table on Incremental Growth
Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem

Exhibit 09: Parent market
Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition

Exhibit 11: Offerings of vendors included in the market definition

3.2 Market segment analysis

Exhibit 12: Market segments

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026

Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary

Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

4.2 Bargaining power of buyers

Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

4.3 Bargaining power of suppliers

Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

4.4 Threat of new entrants

Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

4.5 Threat of substitutes

Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

4.6 Threat of rivalry

Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

4.7 Market condition

Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Disease Type

5.1 Market segments

Exhibit 24: Chart on Disease Type - Market share 2021-2026 (%)
Exhibit 25: Data Table on Disease Type - Market share 2021-2026 (%)

5.2 Comparison by Disease Type

Exhibit 26: Chart on Comparison by Disease Type
Exhibit 27: Data Table on Comparison by Disease Type

5.3 Type 2 diabetes - Market size and forecast 2021-2026

Exhibit 28: Chart on Type 2 diabetes - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Type 2 diabetes - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Type 2 diabetes - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Type 2 diabetes - Year-over-year growth 2021-2026 (%)

5.4 Dumping syndrome - Market size and forecast 2021-2026

Exhibit 32: Chart on Dumping syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Dumping syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Dumping syndrome - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Dumping syndrome - Year-over-year growth 2021-2026 (%)

5.5 Market opportunity by Disease Type

Exhibit 36: Market opportunity by Disease Type ($ million)

6 Customer Landscape

6.1 Customer landscape overview

Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation

Exhibit 38: Chart on Market share by geography 2021-2026 (%)
Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

7.2 Geographic comparison

Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison

7.3 North America - Market size and forecast 2021-2026

Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

7.4 Europe - Market size and forecast 2021-2026

Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

7.5 Asia - Market size and forecast 2021-2026

Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

7.6 Rest of World (ROW) - Market size and forecast 2021-2026

Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

7.7 US - Market size and forecast 2021-2026

Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

7.8 Germany - Market size and forecast 2021-2026

Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

7.9 UK - Market size and forecast 2021-2026

Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)

7.10 China - Market size and forecast 2021-2026

Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)

7.11 Japan - Market size and forecast 2021-2026

Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)

7.12 Market opportunity by geography

Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges

Exhibit 79: Impact of drivers and challenges in 2021 and 2026

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape

Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

9.3 Landscape disruption

Exhibit 81: Overview on factors of disruption

9.4 Industry risks

Exhibit 82: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered

Exhibit 83: Vendors covered

10.2 Market positioning of vendors

Exhibit 84: Matrix on vendor position and classification

10.3 Anderson Hay and Grain Co. Inc.

Exhibit 85: Anderson Hay and Grain Co. Inc. - Overview
Exhibit 86: Anderson Hay and Grain Co. Inc. - Product / Service
Exhibit 87: Anderson Hay and Grain Co. Inc. - Key offerings

10.4 Bayer AG

Exhibit 88: Bayer AG - Overview
Exhibit 89: Bayer AG - Business segments
Exhibit 90: Bayer AG - Key offerings
Exhibit 91: Bayer AG - Segment focus

10.5 Border Valley Trading

Exhibit 92: Border Valley Trading - Overview
Exhibit 93: Border Valley Trading - Product / Service
Exhibit 94: Border Valley Trading - Key offerings

10.6 Eli Lilly and Co.

Exhibit 95: Eli Lilly and Co. - Overview
Exhibit 96: Eli Lilly and Co. - Product / Service
Exhibit 97: Eli Lilly and Co. - Key offerings

10.7 Glenmark Pharmaceuticals Ltd

Exhibit 98: Glenmark Pharmaceuticals Ltd - Overview
Exhibit 99: Glenmark Pharmaceuticals Ltd - Product / Service
Exhibit 100: Glenmark Pharmaceuticals Ltd - Key offerings

10.8 Merck KGaA

Exhibit 101: Merck KGaA - Overview
Exhibit 102: Merck KGaA - Business segments
Exhibit 103: Merck KGaA - Key news
Exhibit 104: Merck KGaA - Key offerings
Exhibit 105: Merck KGaA - Segment focus

10.9 Pfizer Inc.

Exhibit 106: Pfizer Inc. - Overview
Exhibit 107: Pfizer Inc. - Product / Service
Exhibit 108: Pfizer Inc. - Key news
Exhibit 109: Pfizer Inc. - Key offerings

10.10 Sanofi

Exhibit 110: Sanofi - Overview
Exhibit 111: Sanofi - Business segments
Exhibit 112: Sanofi - Key news
Exhibit 113: Sanofi - Key offerings
Exhibit 114: Sanofi - Segment focus

10.11 Sun Pharmaceutical Industries Ltd.

Exhibit 115: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 116: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 117: Sun Pharmaceutical Industries Ltd. - Key offerings

10.12 Takeda Pharmaceutical Co. Ltd.

Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 119: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 121: Takeda Pharmaceutical Co. Ltd. - Key offerings

11 Appendix

11.1 Scope of the report

11.2 Inclusions and exclusions checklist

Exhibit 122: Inclusions checklist
Exhibit 123: Exclusions checklist

11.3 Currency conversion rates for US$

Exhibit 124: Currency conversion rates for US$

11.4 Research methodology

Exhibit 125: Research methodology
Exhibit 126: Validation techniques employed for market sizing
Exhibit 127: Information sources

11.5 List of abbreviations

Exhibit 128: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

SOURCE Technavio